Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders

Lyudmyla Berim, Myron S. Czuczman

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The year 1997 was pivotal in lymphoma research, as it was the year that the US FDA approved rituximab. Rituximab significantly altered clinical management and outcomes of patients with B-cell malignancies. Despite a high initial response rate, the majority of patients subsequently develop variable degrees of therapeutic resistance to rituximab. Research attempting to understand the mechanisms of rituximab resistance and potential ways to overcome them has given rise to the development of novel targeted immunotherapeutics. This article will update the readers on advances in bioengineering of monoclonal antibodies and immunoconjugates that target CD20, as well as other surface antigens. Some additional novel immunotherapeutics, including small modular immunopharmaceuticals, bispecific monoclonal antibodies, T-cell engaging antibodies and immunoconjugates, will also be discussed.

Original languageEnglish (US)
Pages (from-to)963-979
Number of pages17
JournalFuture Oncology
Volume7
Issue number8
DOIs
StatePublished - Aug 1 2011

Fingerprint

Immunoconjugates
Lymphoproliferative Disorders
Monoclonal Antibodies
Bispecific Antibodies
Bioengineering
Therapeutics
Surface Antigens
Research
Lymphoma
B-Lymphocytes
T-Lymphocytes
Rituximab
Antibodies
Neoplasms

Keywords

  • CD20
  • immunoconjugate
  • lymphoma
  • monoclonal antibody

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. / Berim, Lyudmyla; Czuczman, Myron S.

In: Future Oncology, Vol. 7, No. 8, 01.08.2011, p. 963-979.

Research output: Contribution to journalReview article

@article{1264303a5cdd43aeb9ec2cfba5a8317c,
title = "Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders",
abstract = "The year 1997 was pivotal in lymphoma research, as it was the year that the US FDA approved rituximab. Rituximab significantly altered clinical management and outcomes of patients with B-cell malignancies. Despite a high initial response rate, the majority of patients subsequently develop variable degrees of therapeutic resistance to rituximab. Research attempting to understand the mechanisms of rituximab resistance and potential ways to overcome them has given rise to the development of novel targeted immunotherapeutics. This article will update the readers on advances in bioengineering of monoclonal antibodies and immunoconjugates that target CD20, as well as other surface antigens. Some additional novel immunotherapeutics, including small modular immunopharmaceuticals, bispecific monoclonal antibodies, T-cell engaging antibodies and immunoconjugates, will also be discussed.",
keywords = "CD20, immunoconjugate, lymphoma, monoclonal antibody",
author = "Lyudmyla Berim and Czuczman, {Myron S.}",
year = "2011",
month = "8",
day = "1",
doi = "10.2217/fon.11.79",
language = "English (US)",
volume = "7",
pages = "963--979",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders

AU - Berim, Lyudmyla

AU - Czuczman, Myron S.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - The year 1997 was pivotal in lymphoma research, as it was the year that the US FDA approved rituximab. Rituximab significantly altered clinical management and outcomes of patients with B-cell malignancies. Despite a high initial response rate, the majority of patients subsequently develop variable degrees of therapeutic resistance to rituximab. Research attempting to understand the mechanisms of rituximab resistance and potential ways to overcome them has given rise to the development of novel targeted immunotherapeutics. This article will update the readers on advances in bioengineering of monoclonal antibodies and immunoconjugates that target CD20, as well as other surface antigens. Some additional novel immunotherapeutics, including small modular immunopharmaceuticals, bispecific monoclonal antibodies, T-cell engaging antibodies and immunoconjugates, will also be discussed.

AB - The year 1997 was pivotal in lymphoma research, as it was the year that the US FDA approved rituximab. Rituximab significantly altered clinical management and outcomes of patients with B-cell malignancies. Despite a high initial response rate, the majority of patients subsequently develop variable degrees of therapeutic resistance to rituximab. Research attempting to understand the mechanisms of rituximab resistance and potential ways to overcome them has given rise to the development of novel targeted immunotherapeutics. This article will update the readers on advances in bioengineering of monoclonal antibodies and immunoconjugates that target CD20, as well as other surface antigens. Some additional novel immunotherapeutics, including small modular immunopharmaceuticals, bispecific monoclonal antibodies, T-cell engaging antibodies and immunoconjugates, will also be discussed.

KW - CD20

KW - immunoconjugate

KW - lymphoma

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=80051722000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051722000&partnerID=8YFLogxK

U2 - 10.2217/fon.11.79

DO - 10.2217/fon.11.79

M3 - Review article

VL - 7

SP - 963

EP - 979

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 8

ER -